70 results about "Anticarcinogenic Effect" patented technology

The invention discloses a preparation method and application of roasted barley and malt polysaccharide with an anti-cancer effect. The roasted barley malt polysaccharide is a neutral heteropolysaccharide which mainly takes-> 3)-beta-D-Glcp-(1-> and->-beta-D-Glcp-(1->) as main chains, branches exist at O-3 / O-4 positions, and the branch chains are mainly composed of-> 4)-beta-D-Xylp-(1->,-> 3, 4)-beta-D-Xylp-(1-> and alpha-D-Glcp-(1->. The monosaccharide composition comprises arabinose, glucose and xylose in a molar mass ratio of 1.86: 33.43: 1.00, and the molecular weight is 23.81 kDa. In-vitro activity experiments prove that the roasted barley malt polysaccharide disclosed by the invention has a remarkable inhibition effect on proliferation of liver cancer cells, lung cancer cells, breast cancer cells and colorectal cancer cells, particularly on the liver cancer cells, and shows outstanding anti-tumor activity, so that the roasted barley malt polysaccharide is expected to be developed and applied in the fields of foods, health-care products or medicines.

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

The application discloses a combined drug for treating lung cancer. It is found for the first time that lomethixol can be used alone or in combination with other drugs to have a significant anticancer effect on NSCLC patients and NSCLC patients resistant to osimertinib, and in addition, it is found that lomethixol is a potential autophagy inducer and can activate cell autophagy. The application provides a new clinical treatment method for NSCLC patients and NSCLC patients resistant to osimertinib, and has a wide application prospect.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention relates to a composition containing selenium gluconate and application of the composition in preparation of anti-cancer drugs. The composition comprises a shiitake mushroom extract, a chicory extract and selenium gluconate. Wherein the selenium gluconate is selenium salt of gluconic acid, has an anti-cancer effect, but is easy to generate side effects when being independently used; according to the invention, the mushroom extract, the chicory extract and the selenium gluconate are combined for use, so that the killing power of the composition on cancer cells can be synergistically improved, the immunity can be remarkably improved, the related side effects can be effectively reduced, and the damage to normal cells can be reduced.

The invention relates to the technical field of biological medicines, and particularly discloses a compound or a composition and application of the compound or the composition in preparation of a medicine with an anti-cancer effect. The compound has a structure as shown in a formula I, a formula II or a formula III. Researches show that the compound provided by the invention has an anti-pancreatic cancer effect; further research shows that the composition composed of the compounds with the structures as shown in the formula I and the formula III has a more excellent pancreatic cancer resisting effect, and the pancreatic cancer resisting effect of the composition is greatly higher than that of the single compound with the structure as shown in the formula I or the single compound with the structure as shown in the formula III.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

The present invention pertains to a composition, containing aripiprazole as an active ingredient, for enhancing the anticancer effect of a RAF inhibitor. More specifically, the present invention pertains to a composition for enhancing the anticancer effect of the RAF inhibitor, wherein the composition can treat cancer by acting as an agent for enhancing the anticancer effect of the RAF inhibitor when used in combination therapy with aripiprazole. Administering an effective amount of aripiprazole according to the present invention in combination with the RAF inhibitor is highly effective in enhancing the anticancer effect of the RAF inhibitor, such as by inducing cancer cell death, and thus the composition can be advantageously used as an agent for enhancing the anticancer effect of the RAF inhibitor.

The present invention relates to: an antibody targeting a mutation of KRAS as an intracellular oncoprotein; or a fusion protein in which a cancer cell-penetrating peptide is linked to a single-chain variable fragment of the antibody by a genetic expression method or a chemical bonding method; and a tumor therapeutic use thereof. The fusion protein thus produced has the benefit of maximizing an anti-tumor or anticancer effect of the antibody or the single-chain variable fragment of the antibody targeting an intracellular oncoprotein or an oncomutant protein by effectively invading tumor cells.

The present invention addresses the problem of developing a drug for inhibiting the DNA damage restoration mechanism in a cancer which does not have a mutation in BRCA 1 / 2 and in which homologous recombination repair functions normally.　The inventors of the present invention have clarified that cell death can be induced by inhibiting PARP functions and mitochondrial respiration functions in cells, and indicated that the problem can be solved. In other words, the present invention provides: a method for inducing cell death by inhibiting PARP functions and mitochondrial respiration functions in cells; and a pharmaceutical composition for treating cancer, the pharmaceutical composition containing a PARP inhibitor and a mitochondrial respiration inhibitor.

The present application relates to the field of immunology, in particular to anti-LILRB1 antibodies or antigen-binding fragments thereof, preparation methods and uses, especially anti-LILRB1 nanobodies or antigen-binding fragments thereof, preparation methods and uses. The anti-LILRB1 antibodies or antigen-binding fragments thereof can inhibit the immune escape mechanism of tumor cells, so that immune cells can exhibit their anti-cancer effects.

The present invention relates to the use of sodium pentaborate pentahydrate enriched with boron isotope (10B, 11B) as a chemotherapeutic agent thanks to its anticarcinogenic effect on renal cancer. As a result of the experimental studies performed within the scope of the invention, it has been shown that while the number of renal cancer cells decreased by 50%, this effect occurs by arresting the cell cycle and slowing down cell proliferation, therefore sodium pentaborate pentahydrate enriched with boron isotope can be used as a chemotherapeutic agent in cancer treatment.

The present invention relates to the field of biomedicine technology, and specifically discloses a thiophene-containing pyrimidine compound, a preparation method thereof, and its use in the preparation of drugs with anti-cancer effects. The thiophene-containing pyrimidine compound has a chemical structure represented by formula (I). Studies have shown that the thiophene-containing pyrimidine compound has an inhibitory effect on PLK1 protein kinase; therefore, using it as an active ingredient in the preparation of drugs with anti-cancer effects has important application value. In particular, in existing anti-cancer experiments, the thiophene-containing pyrimidine compound has a better effect on non-small cell lung cancer than the known compound BI2536, showing a more significant anti-non-small cell lung cancer effect.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

The invention relates to a composition used as an anti-carcinogenic agent having low cardiotoxicity and high antimicrobial stability. The composition comprises at least one fraction of Heteroctenus junceus scorpion venom, wherein said fraction can be selected from the list comprising: F4, F5.3 and any recognisable and identifiable combination of the two, wherein both fractions have an anti-carcinogenic effect, which is mainly associated with the total or partial inhibition of tumour progression.

The present invention relates to a composition for enhancing the anticancer effect of a MEK inhibitor, the composition comprising aripiprazole as an active ingredient, and more specifically, to a composition for enhancing the anticancer effect of a MEK inhibitor, the composition being capable of treating cancer by acting as an anticancer effect enhancer of the MEK inhibitor when used in combination therapy with aripiprazole, wherein an effective amount of aripiprazole according to the present invention is highly effective in improving the anticancer effect of the MEK inhibitor, such as by inducing cancer cell death, when administered in combination with the MEK inhibitor, and thus the present invention can be effectively used as an agent for improving the anticancer effect of the MEK inhibitor.

This invention discloses an epigenetic drug targeting lncRNA-PSF interaction, its composition, and its application. First, this invention synthesizes an epigenetic drug targeting lncRNA-PSF interaction as shown in formula (I) or formula (II). Compared with existing technologies, the epigenetic drugs shown in formulas (I) and (II) can inhibit lncRNA-PSF interaction, alter the cell cycle by increasing the expression of p27 and p53 proteins, arrest cancer cells in the G2 / M phase, and thus exert an anti-cancer effect. When the epigenetic drugs shown in formulas (I) and (II) are used in combination with immunosuppressants, they can enhance the effect of immunosuppressants, increase antigen presentation by cancer cells, and reduce their immune escape, thus becoming a novel anti-cancer sensitization strategy.

The invention discloses a selenium vitamin E capsule composition for resisting cancer and assisting in protecting chemical liver injury, and belongs to the technical field of health food. The composition is prepared from active ingredients and pharmaceutic adjuvants, wherein the active ingredients comprise L-selenium-methyl selenocysteine, vitamin E, vitamin C and vitamin B3. All the active ingredients generate a synergistic effect through scientific proportioning, so that the composition not only can effectively inhibit cancer cell proliferation and play an anti-cancer role, but also can relieve damage of chemical toxins to the liver through a strong anti-oxidation mechanism and assist in protecting the liver function. The product disclosed by the invention is high in bioavailability and good in safety, and has remarkable beneficial effects.

A fusion protein comprising a LIGHT protein and an antigen-binding domain that specifically binds to FAP may exhibit anti-cancer effects. In particular, the fusion protein efficiently targets cancer cells which overexpress FAP, and LIGHT may bind to a lymphotoxin beta receptor and HVEM to promote the formation of tertiary lymphoid structures and normalize blood vessels. Accordingly, the fusion protein enables effective treatment of cancer through efficient infiltration of immune cells into tumor tissue. Furthermore, it was confirmed that the fusion protein of the present invention can treat cancer more effectively when administered in combination with an anti-PD-1 antibody compared to when administered individually.

To provide a composition that enables improvement of a cancer microenvironment, suppression of immune exclusion, inhibition of fibroblast differentiation, promotion of T cell infiltration into tumor tissue, or enhancement of the anti-cancer effect of an immune checkpoint inhibitor.SOLUTION: A composition comprising a circadian rhythm period extending agent for use in at least one selected from the group consisting of improvement of a cancer microenvironment, suppression of immune exclusion, inhibition of fibroblast differentiation, promotion of T cell infiltration into tumor tissue, and enhancement of the anti-cancer effect of an immune checkpoint inhibitor.SELECTED DRAWING: None

The invention belongs to the technical field of polypeptide drugs, and particularly relates to a series of polypeptides with an anti-cancer effect and application thereof. According to the invention, Rink amide MBHA amino resin is used as a solid phase carrier, modification is carried out according to an amino acid sequence of a template polypeptide Hymenochirin-1Pa (H-0): Ac-LKLSPKTKDTLKKVLKGAIKGAIAIASAMA-NH2, and on the basis of retaining key amino acid residues, original amino acids are replaced by R8 and S5 at the positions of i and i + 7 amino acids, so that the target stapling peptide is obtained. Compared with a template polypeptide H-0, the obtained stapled peptide has the advantage that the anti-tumor activity on human liver cancer cells Huh7, human non-small cell lung cancer cells A549, glioma cells U87 and colon cancer cells T84 can be obviously improved.

The invention discloses an 8-hydroxyquinoline platinum complex as well as a preparation method and application thereof. The preparation method comprises the following steps: reacting 5, 7-dichloro-8-hydroxyquinoline, 5-chloro-7-iodine-8-hydroxyquinoline or 5, 7-dibromo-8-hydroxyquinoline with platinum salt cis-[PtCl2 (DMSO) 2], synthesizing to obtain an intermediate, and synthesizing the intermediate and an auxiliary ligand phenanthroline derivative to obtain the 8-hydroxyquinoline platinum complex. Experimental results show that the 8-hydroxyquinoline platinum complex has a good anti-cancer effect on SK-BR-3 cancer cells and almost has no toxicity on normal LO2 cells, which indicates that the 8-hydroxyquinoline platinum complex can inhibit the growth of the SK-BR-3 cancer cells in a targeted manner. The 8-hydroxyquinoline platinum complex shows excellent anti-tumor activity, has potential medicinal value, and is expected to be used for preparing various anti-tumor drugs.

The present invention relates to a highly active transposase protein for a transposon system and its uses. By improving the activity of the transposase, genes can be delivered effectively, which can be useful for developing genome-modified cell lines that express various genes. In addition, when T cells are transformed using the highly active transposase of the present invention, cytotoxic T cells (CD8) that have anti-cancer effects can be generated. + The proportion of T cells increases, and T cells persist in the body. CM (Central memory T cell), T SCM Since the proportion of memory-type T cells (stem cell-like memory T cells) increased, it is expected that TCR-T cells and CAR-T cells with good in vivo persistence can be produced using the transposon system of the present invention.

This invention discloses the application of gluconate compounds in the preparation of drugs for the prevention and treatment of ovarian cancer. The gluconate compounds include at least one of sodium gluconate, potassium gluconate, calcium gluconate, and zinc gluconate. The invention also discloses the application of gluconate compounds in the preparation of inhibitors of the interaction between TMEM87A protein and CHP1 protein. This invention is the first to discover and demonstrate that gluconate compounds possess significant anti-ovarian cancer activity, effectively inhibiting the proliferation and metastasis of ovarian cancer cells. It also reveals for the first time a novel anti-cancer mechanism by which sodium gluconate directly binds to TMEM87A protein and disrupts the functional complex formed between TMEM87A and CHP1 protein. This invention overcomes the technical prejudice commonly held by those skilled in the art that gluconates are merely nutritional supplements or chelating agents, providing a novel, safe, and widely available class of candidate drugs for the treatment of ovarian cancer.

The present application provides the use of a flavonoid extract of Polygonatum sibiricum in the preparation of drugs for treating colorectal cancer, and belongs to the field of biomedicine technology. The flavonoid extract of Polygonatum sibiricum and the high-isoflavonoid compounds of the present application exert excellent anti-cancer effects by inhibiting cancer cell proliferation, inducing cancer cell apoptosis and DNA damage. The above-mentioned drugs are highly safe, low-cost, and have good anti-cancer effects. In addition, the high-isoflavonoid compounds can also be used in combination with traditional chemotherapy drugs (such as 5-FU) to exert a synergistic and effective effect, with excellent results. The present application has good clinical application prospects.